Marksans Pharma (MARKSANS) 주식 개요
마크산스 파마는 자회사와 함께 미국, 북미, 유럽, 영국, 호주, 뉴질랜드 및 전 세계에서 의약품 연구, 제조, 마케팅 및 판매에 종사하고 있습니다. 자세히 보기
MARKSANS Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marksans Pharma Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | ₹259.70 |
| 52주 최고가 | ₹278.80 |
| 52주 최저가 | ₹155.00 |
| 베타 | 1.09 |
| 1개월 변동 | 11.37% |
| 3개월 변동 | 52.76% |
| 1년 변동 | 0.89% |
| 3년 변동 | 184.29% |
| 5년 변동 | 195.11% |
| IPO 이후 변동 | 854.96% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.
새로운 내러티브 • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Recent updates
내러티브 업데이트 • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.새로운 내러티브 • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
새로운 내러티브 • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?분석 기사 • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...분석 기사 • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...분석 기사 • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...분석 기사 • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...내러티브 업데이트 • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.분석 기사 • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...내러티브 업데이트 • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.분석 기사 • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...분석 기사 • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...분석 기사 • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...분석 기사 • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...분석 기사 • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...분석 기사 • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...분석 기사 • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...분석 기사 • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
새로운 내러티브 • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.분석 기사 • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...분석 기사 • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...분석 기사 • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...분석 기사 • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...분석 기사 • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...분석 기사 • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...주주 수익률
| MARKSANS | IN Pharmaceuticals | IN 시장 | |
|---|---|---|---|
| 7D | -1.4% | 3.3% | 1.0% |
| 1Y | 0.9% | 12.6% | -1.4% |
수익률 대 산업: MARKSANS은 지난 1년 동안 12.6%의 수익을 기록한 Indian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: MARKSANS은 지난 1년 동안 -1.4%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
안정적인 주가: MARKSANS는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MARKSANS의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1992 | 1,840 | Mark Saldanha | marksanspharma.com |
마크산스 파마는 자회사와 함께 미국, 북미, 유럽, 영국, 호주, 뉴질랜드 및 전 세계에서 의약품 연구, 제조, 마케팅 및 판매에 종사하고 있습니다. 이 회사는 통증 관리, 상기도, 심혈관, 중추신경계, 항당뇨, 위장, 진통제, 상기도, 귀 관리, 스킨케어, 항암, 항궤양, 항알레르기, 항바이러스, 다이어트, 심장, 피부과, 항히스타민, 항진균, 항바이러스, 완하제, 감기 및 기침 치료 분야의 제품을 제공합니다. 또한 정제 및 경질 젤라틴 캡슐, 소프트 젤, 에센셜 오일, 연고, 크림 및 액상, 처방약 등 다양한 고형 경구 투여 형태도 생산합니다.
Marksans Pharma Limited 기초 지표 요약
| MARKSANS 기초 통계 | |
|---|---|
| 시가총액 | ₹119.84b |
| 순이익 (TTM) | ₹4.18b |
| 매출 (TTM) | ₹29.51b |
28.2x
주가수익비율(P/E)4.0x
주가매출비율(P/S)MARKSANS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MARKSANS 손익계산서 (TTM) | |
|---|---|
| 매출 | ₹29.51b |
| 매출원가 | ₹12.77b |
| 총이익 | ₹16.74b |
| 기타 비용 | ₹12.56b |
| 순이익 | ₹4.18b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 9.22 |
| 총이익률 | 56.72% |
| 순이익률 | 14.16% |
| 부채/자본 비율 | 1.0% |
MARKSANS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Marksans Pharma 배당 일정 | |
|---|---|
| 배당락일 | Aug 20 2026 |
| 배당 지급일 | Sep 26 2026 |
| 배당락일까지 남은 일수 | 44 days |
| 배당 지급일까지 남은 일수 | 81 days |
MARKSANS는 안정적으로 배당을 지급합니까?
MARKSANS 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/06 14:59 |
| 종가 | 2026/07/06 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Marksans Pharma Limited는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |